NVAX Share Price

Open 1.20 Change Price %
High 1.21 1 Day -0.01 -0.84
Low 1.13 1 Week 0.08 7.27
Close 1.18 1 Month 0.16 15.69
Volume 12259637 1 Year -5.48 -82.28
52 Week High 8.49
52 Week Low 0.73
NVAX Important Levels
Resistance 2 1.25
Resistance 1 1.22
Pivot 1.17
Support 1 1.14
Support 2 1.11
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 2.5
As on 23rd Jun 2017 NVAX Share Price closed @ 1.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.32 & Strong Buy for SHORT-TERM with Stoploss of 0.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for June
1st Target up-side 1.18
2nd Target up-side 1.36
3rd Target up-side 1.54
1st Target down-side 0.66
2nd Target down-side 0.48
3rd Target down-side 0.3
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.